Geode Capital Management’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-633,253
| Closed | -$37.9M | – | 4275 |
|
|
2019
Q4 | $37.9M | Buy |
633,253
+34,548
| +6% | +$1.3M | 0.01% | 1124 |
|
|
2019
Q3 | $16.8M | Buy |
598,705
+85,321
| +17% | +$2.91M | ﹤0.01% | 1601 |
|
|
2019
Q2 | $19.4M | Buy |
513,384
+74,354
| +17% | +$2.86M | ﹤0.01% | 1503 |
|
|
2019
Q1 | $17.1M | Buy |
439,030
+44,575
| +11% | +$1.28M | ﹤0.01% | 1526 |
|
|
2018
Q4 | $8.41M | Buy |
394,455
+56,856
| +17% | +$1.47M | ﹤0.01% | 1888 |
|
|
2018
Q3 | $13.4M | Buy |
337,599
+22,649
| +7% | +$844K | ﹤0.01% | 1709 |
|
|
2018
Q2 | $12M | Buy |
314,950
+84,700
| +37% | +$3.14M | ﹤0.01% | 1735 |
|
|
2018
Q1 | $6.92M | Buy |
230,250
+28,126
| +14% | +$952K | ﹤0.01% | 2033 |
|
|
2017
Q4 | $6.32M | Buy |
202,124
+23,041
| +13% | +$633K | ﹤0.01% | 2075 |
|
|
2017
Q3 | $5.02M | Buy |
179,083
+13,300
| +8% | +$289K | ﹤0.01% | 2209 |
|
|
2017
Q2 | $3.17M | Buy |
165,783
+121,363
| +273% | +$1.94M | ﹤0.01% | 2458 |
|
|
2017
Q1 | $756K | Buy |
44,420
+1,591
| +4% | +$25.7K | ﹤0.01% | 3148 |
|
|
2016
Q4 | $782K | Buy |
42,829
+28,600
| +201% | +$494K | ﹤0.01% | 3105 |
|
|
2016
Q3 | $253K | Buy |
+14,229
| New | +$216K | ﹤0.01% | 3516 |
|
Geode Capital Management's BOLD Position: Q1 2020 in Review
Geode Capital Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 633,253 shares — an estimated $37.9M sold.
Geode Capital Management first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $37.9M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Geode Capital Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Geode Capital Management sold 633,253 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $37.9M.
- Geode Capital Management first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- Geode Capital Management's Audentes Therapeutics, Inc position peaked at $37.9M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Geode Capital Management's 13F filing for Q1 2020, filed 14 May 2020.